Secular Trends in Opportunistic Infections, Cancers and Mortality in Patients With Aids During the Era of Modern Combination Antiretroviral Therapy
| dc.contributor.author | Sezgin, Efe | |
| dc.contributor.author | Van Natta, Mark L. | |
| dc.contributor.author | Thorne, Jennifer E. | |
| dc.contributor.author | Puhan, M. A. | |
| dc.contributor.author | Jabs, D. A. | |
| dc.coverage.doi | 10.1111/hiv.12609 | |
| dc.date.accessioned | 2020-01-17T08:59:47Z | |
| dc.date.available | 2020-01-17T08:59:47Z | |
| dc.date.issued | 2018 | |
| dc.description.abstract | Objectives: The aim of the study was to estimate the incidence of, determine risk factors for, and investigate the consequences of opportunistic infections (OIs) and malignancies among patients with the acquired immune deficiency syndrome (AIDS) in the era of modern combination antiretroviral therapy (cART). Methods: Three enrolment periods (1998–2002, 2003–2005 and 2006–2012), corresponding to changes in predominant cART regimens, were compared among 1889 participants enrolled in a prospective cohort study, the Longitudinal Study of Ocular Complications of AIDS (LSOCA). Incidences of AIDS-related OIs and cancers were estimated. Multivariate logistic and Cox regression models were used to determine the effect of demographic and clinical characteristics on OIs and mortality. Results: Between participants enrolled in the 1998–2002 and 2006–2012 enrolment periods, the incidence of OIs decreased from 27 per 1000 person-years (PY) to 11 per 1000 PY (P < 0.001), and mortality decreased from 41 per 1000 PY to 18 per 1000 PY (P < 0.0001), corresponding to improvements in cART regimens. Conclusions: Improvements in cART regimens led to a progressive decline in the incidence of OIs and mortality between 1999 and 2013 among patients with AIDS in the era of modern cART. | en_US |
| dc.description.sponsorship | National Eye Institute, the National Institutes of Health, Bethesda, MD (U10 EY 08052); Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD (U10 EY 08057); University of Wisconsin, Madison School of Medicine, Madison, WI (U10 EY 08067); Johns Hopkins Center for AIDS Research grant from the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, Bethesda, MD, USA (1P30AI094189); TUBITAK (116C090) | en_US |
| dc.identifier.citation | Sezgin, E., Van Natta, M. L., Thorne, J. E., Puhan, M. A., and Jabs, D. A. (2018). Secular trends in opportunistic infections, cancers and mortality in patients with AIDS during the era of modern combination antiretroviral therapy. HIV Medicine, 19(6), 411-419. doi:10.1111/hiv.12609 | en_US |
| dc.identifier.doi | 10.1111/hiv.12609 | en_US |
| dc.identifier.doi | 10.1111/hiv.12609 | |
| dc.identifier.issn | 1464-2662 | |
| dc.identifier.scopus | 2-s2.0-85044314262 | |
| dc.identifier.uri | https://doi.org/10.1111/hiv.12609 | |
| dc.identifier.uri | https://hdl.handle.net/11147/7598 | |
| dc.language.iso | en | en_US |
| dc.publisher | John Wiley and Sons Inc. | en_US |
| dc.relation.ispartof | HIV Medicine | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | AIDS | en_US |
| dc.subject | Opportunistic infection | en_US |
| dc.subject | Antiretroviral therapy | en_US |
| dc.subject | Integrase inhibitor | en_US |
| dc.subject | AIDS related complex | en_US |
| dc.subject | Mortality rate | en_US |
| dc.title | Secular Trends in Opportunistic Infections, Cancers and Mortality in Patients With Aids During the Era of Modern Combination Antiretroviral Therapy | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.id | 0000-0002-8000-7485 | |
| gdc.author.institutional | Sezgin, Efe | |
| gdc.bip.impulseclass | C4 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C4 | |
| gdc.coar.access | open access | |
| gdc.coar.type | text::journal::journal article | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | İzmir Institute of Technology. Food Engineering | en_US |
| gdc.description.endpage | 419 | en_US |
| gdc.description.issue | 6 | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q2 | |
| gdc.description.startpage | 411 | en_US |
| gdc.description.volume | 19 | en_US |
| gdc.description.wosquality | Q2 | |
| gdc.identifier.openalex | W2792958190 | |
| gdc.identifier.pmid | 29573311 | |
| gdc.identifier.wos | WOS:000435938300007 | |
| gdc.index.type | WoS | |
| gdc.index.type | Scopus | |
| gdc.index.type | PubMed | |
| gdc.oaire.accesstype | BRONZE | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.downloads | 0 | |
| gdc.oaire.impulse | 12.0 | |
| gdc.oaire.influence | 3.474972E-9 | |
| gdc.oaire.isgreen | true | |
| gdc.oaire.keywords | Adult | |
| gdc.oaire.keywords | Male | |
| gdc.oaire.keywords | opportunistic infection | |
| gdc.oaire.keywords | AIDS-related cancer | |
| gdc.oaire.keywords | 610 Medicine & health | |
| gdc.oaire.keywords | Opportunistic infection | |
| gdc.oaire.keywords | Risk Factors | |
| gdc.oaire.keywords | Antiretroviral Therapy, Highly Active | |
| gdc.oaire.keywords | Neoplasms | |
| gdc.oaire.keywords | 2736 Pharmacology (medical) | |
| gdc.oaire.keywords | Humans | |
| gdc.oaire.keywords | Longitudinal Studies | |
| gdc.oaire.keywords | Prospective Studies | |
| gdc.oaire.keywords | Integrase inhibitor | |
| gdc.oaire.keywords | AIDS related complex | |
| gdc.oaire.keywords | Acquired Immunodeficiency Syndrome | |
| gdc.oaire.keywords | AIDS-Related Opportunistic Infections | |
| gdc.oaire.keywords | HIV | |
| gdc.oaire.keywords | 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI) | |
| gdc.oaire.keywords | 2725 Infectious Diseases | |
| gdc.oaire.keywords | Middle Aged | |
| gdc.oaire.keywords | 2719 Health Policy | |
| gdc.oaire.keywords | mortality | |
| gdc.oaire.keywords | Mortality rate | |
| gdc.oaire.keywords | Antiretroviral therapy | |
| gdc.oaire.keywords | CD4 Lymphocyte Count | |
| gdc.oaire.keywords | AIDS | |
| gdc.oaire.keywords | Population Surveillance | |
| gdc.oaire.keywords | Drug Therapy, Combination | |
| gdc.oaire.keywords | Female | |
| gdc.oaire.popularity | 9.238275E-9 | |
| gdc.oaire.publicfunded | false | |
| gdc.oaire.sciencefields | 0301 basic medicine | |
| gdc.oaire.sciencefields | 03 medical and health sciences | |
| gdc.oaire.sciencefields | 0302 clinical medicine | |
| gdc.oaire.views | 6 | |
| gdc.openalex.collaboration | International | |
| gdc.openalex.fwci | 2.44389994 | |
| gdc.openalex.normalizedpercentile | 0.86 | |
| gdc.opencitations.count | 16 | |
| gdc.plumx.crossrefcites | 15 | |
| gdc.plumx.mendeley | 34 | |
| gdc.plumx.pubmedcites | 8 | |
| gdc.plumx.scopuscites | 16 | |
| gdc.scopus.citedcount | 16 | |
| gdc.wos.citedcount | 16 | |
| relation.isAuthorOfPublication.latestForDiscovery | 77721b7d-10bb-4a8e-8cd8-10a1088bfb1b | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 9af2b05f-28ac-4019-8abe-a4dfe192da5e |
